摘要
探讨左乙拉西坦联合胸腺肽治疗儿童难治性癫痫临床疗效及对患儿血清T细胞亚群、免疫球蛋白水平的影响。方法将94例难治性癫痫患儿采用随机数字表法分为观察组与对照组,各47例。两组均给予左乙拉西坦治疗,观察组在此基础上给予胸腺肽治疗。比较两组临床疗效及治疗前后血清T细胞亚群、免疫球蛋白水平变化情况。结果观察组治疗总有效率高于对照组(P<0.05),治疗后观察组CD3^+、CD4^+、CD4^+/CD8^+水平显著高于治疗前(P<0.01),CD8^+水平显著低于治疗前(P<0.01),对照组CD4^+/CD8^+水平显著高于治疗前,观察组较对照组变化更显著(P<0.01)。治疗后观察组IgA、IgG水平显著高于治疗前(P<0.01),且显著高于对照组(P<0.01)。结论左乙拉西坦联合胸腺肽治疗难治性癫痫患儿效果显著,可有效改善血清T细胞亚群及免疫球蛋白水平,值得临床推广。
Objective To investigate the clinical efficacy of levetiracetam combined with thymosin in the treatment of refractory epilepsy and its effect on serum T cell subsets and immunoglobulin levels. Methods 94 cases of children with refractory epilepsy were randomly divided into observation group and control group, 47 cases in each group. Both groups were treated with levetiracetam, and the observation group was given thymosin treatment on this basis. Compare the clinical efficacy of the two groups and the changes of serum T cell subsets and immunoglobulin levels before and after treatment. Results The total effective rate of the observation group was higher than that of the control group (P<0. 05). The levels of CD3^+, CD4^+, CD4^+/CD8^+ in the observation group after treatment were significantly higher than those before treatment ( P<0.01), and the level of CD8+ was significantly lower than that before treatment (P<0. 05),the CD4^+/CD8^+ level in the control group was significantly higher than that before treatment,and the observation group changed more significantly than the control group ( P<0. 01). After treatment, the levels of IgA and IgG in the observation group were significantly higher than those before treatment (P<0.01) and significantly higher than the control group (P<0.01). Conclusion Levetirac-etam combined with thymosin is effective in the treatment of children with refractory epilepsy, which can effectively improve serum T cell subsets and immunoglobulin levels, which is worthy of clinical promotion.
作者
刘琳
付荣
李丽娜
Liu Lin;Fu Rong;Li Lina(Puyang Oilfield General Hospital,Puyang 457001,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第1期14-16,27,共4页
Journal of Clinical Psychosomatic Diseases
基金
2015年河南省科技发展计划项目(编号152102310020).
